Provided by Tiger Trade Technology Pte. Ltd.

Neurosense Therapeutics Ltd

3.49
+0.01000.29%
Post-market: 3.950.4557+13.06%19:50 EDT
Volume:43.22K
Turnover:153.70K
Market Cap:6.59M
PE:-0.40
High:3.78
Open:3.77
Low:3.37
Close:3.48
52wk High:26.64
52wk Low:3.28
Shares:1.89M
Float Shares:1.29M
Volume Ratio:3.11
T/O Rate:3.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.7319
EPS(LYR):-8.7319
ROE:-2174.98%
ROA:-247.30%
PB:-4.22
PE(LYR):-0.40

Loading ...

NeuroSense Plans Head-to-Head PrimeC Trial Versus Mitsubishi Tanabe’s Edaravone in ALS

Reuters
·
Aug 31

Neurosense Unveils Accelerated, Capital-Efficient Strategy to Advance Primec Toward Potential Approval in ALS

THOMSON REUTERS
·
Aug 31

NeuroSense Therapeutics Shareholders Authorized Board to Pursue Reverse Stock Split Range 1-for-4 to 1-for-40

Reuters
·
Aug 28

NeuroSense Announces Shareholder Letter Availability

Reuters
·
Aug 13

NeuroSense Targets December 2026 Canada Filing for PrimeC ALS Drug Amid Phase 3 Paragon Preparations

Reuters
·
Aug 13

Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN) and Brookdale Senior Living (BKD)

TIPRANKS
·
Aug 11

NeuroSense sees December 2026 as filing date for NDS for PrimeC

TIPRANKS
·
Aug 06

NeuroSense Therapeutics Announces Special Shareholder Meeting

Reuters
·
Aug 01

NeuroSense Amends JonesTrading Equity Distribution Agreement for up to $3.79 Million Share Sales

Reuters
·
Aug 01

Neurosense Therapeutics Ltd Expected to Post Breakeven Results a Share - Earnings Preview

Reuters
·
Jul 28

Neurosense Therapeutics - Expects to File Submission to Health Canada in Coming Months

THOMSON REUTERS
·
Jul 22

Neurosense Therapeutics Announces Press Release Availability

Reuters
·
Jul 22

Neurosense Plans Primec New Drug Filing with Health Canada for ALS

Reuters
·
Jul 22

Neurosense Therapeutics Ltd. (NRSN) Gets a Buy from Noble Financial

TIPRANKS
·
Jul 02

Neurosense Therapeutics Achieves Primary Endpoint in Phase 2B ALS Study

Reuters
·
Jun 29

Neurosense Rises as Nerve Disease Drug Shows Promise in Study

Reuters
·
Jun 29

NeuroSense says Phase 2b PARADIGM study of PrimeC in ALS met endpoint

TIPRANKS
·
Jun 29

Neurosense Says Phase 2b ALS Trial Meets Primary Endpoint, Cuts Tdp-43 vs Placebo (p=0.0421)

Reuters
·
Jun 29

Neurosense Achieves Primary Endpoint in Phase 2B ALS Study with Statistically Significant Reduction of Tdp-43, the Defining Pathological Hallmark of ALS

THOMSON REUTERS
·
Jun 29

Neurosense Therapeutics - Primec Shows Favorable Safety Profile with no New Safety Signals over 18 Months

THOMSON REUTERS
·
Jun 29